<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00027560</url>
  </required_header>
  <id_info>
    <org_study_id>01-092</org_study_id>
    <secondary_id>MSKCC-01092</secondary_id>
    <secondary_id>NCI-G01-2028</secondary_id>
    <nct_id>NCT00027560</nct_id>
  </id_info>
  <brief_title>Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer</brief_title>
  <official_title>Phase II Trial Of Non-Myeloablative Regimen Combining Melphalan, Fludarabine, And Anti-CD52 Monoclonal Antibody (CAMPATH-1H) Followed By An Unmodified Hematopoietic Cell Transplant From An HLA Compatible Related Or Unrelated Donor For Treatment Of Lymphohematopoietic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy, such as melphalan and fludarabine, and a
      monoclonal antibody, such as alemtuzumab, before a donor bone marrow or peripheral blood stem
      cell transplant helps stop the growth of cancer cells. It also stops the patient's immune
      system from rejecting the donor's stem cells. The donated stem cells may replace the
      patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor
      effect). Sometimes the transplanted cells from a donor can also make an immune response
      against the body's normal cells. Giving cyclosporine after the transplant may stop this from
      happening.

      PURPOSE: This phase II trial is studying how well fludarabine, melphalan, alemtuzumab, and
      peripheral stem cell transplant work in treating patients with hematologic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Overall survival-12 months

      Overall survival-24 months

      Acute Graft-versus-Host Disease Matched Related patients-up to 4 months post transplant

      Acute Graft-versus-Host Disease Unrelated and Mismatched related patients- up to 4 months
      post transplant

      Chronic Graft-versus-Host Disease Matched Related patients- up to 2 years post transplant

      Chronic Graft-versus-host disease Unrelated and Mismatched related patients- up to 2 years
      post transplant

        -  OUTLINE: Patients are stratified according to donor type (HLA-matched related vs
           HLA-matched unrelated, single HLA-allele disparate related, or unmatched)
           (HLA-mismatched related or matched unrelated donor stratum closed to accrual as of
           1/11/06).

      Patients receive a nonmyeloablative regimen comprising alemtuzumab IV over 8 hours on days -8
      to -5, fludarabine IV over 30 minutes on days -8 to -4, and melphalan IV over 30 minutes on
      days -3 and -2. Allogeneic peripheral blood stem cells or bone marrow is infused on day 0.

      Patients receive graft-versus host disease prophylaxis comprising cyclosporine IV every 12
      hours beginning on day -1 and continuing orally as tolerated until day 100.

      Patients are followed every 6 weeks for 6 months, every 3 months for 6 months, every 3-6
      months for 1 year, and then annually thereafter or as clinically indicated.

      PROJECTED ACCRUAL: A maximum of 50 patients (25 HLA-matched related and 25 HLA-mismatched
      related or matched unrelated) will be accrued for this study within 2 years (HLA-mismatched
      related or matched unrelated donor stratum closed to accrual as of 1/11/06).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2001</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>12 months post transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>24 months post transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute Graft-versus-Host Disease Matched Related Patients</measure>
    <time_frame>up to 4 months post transplant</time_frame>
    <description>Grade III-IV Acute Graft-versus-Host Disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Graft-versus-Host Disease Unrelated and Mismatched Related Patients</measure>
    <time_frame>up to 4 months post transplant</time_frame>
    <description>Grade III-IV Acute Graft-versus-Host Disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extensive Chronic Graft-versus-Host Disease Matched Related Patients</measure>
    <time_frame>up to 2 years post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extensive Chronic Graft-versus-Host Disease Unrelated and Mismatched Related Patients</measure>
    <time_frame>up to 2 years post transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <arm_group>
    <arm_group_label>TREATMENT OF LYMPHOHEMATOPOIETIC MALIGNANCIES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a stratified single-armed phase II study designed to investigate the safety and efficacy of hematopoietic cell allografts administered after nonmyeloablative cytoreduction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>alemtuzumab</intervention_name>
    <description>Consenting individuals will receive pretransplant immunosuppressive cytoreduction, which will consist of 4 days of Campath-1H, 5 days of fludarabine, and two days of melphalan. All therapy should be completed approximately 24-36 hours before administration of the primary allograft.
Campath-1H (20mg/dose/day) will be administered for each of four days from day -8 to day -5, inclusive. Each dose will be infused intravenously over 8 hours.</description>
    <arm_group_label>TREATMENT OF LYMPHOHEMATOPOIETIC MALIGNANCIES</arm_group_label>
    <other_name>Campath</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Patients will be treated with Cyclosporine as prophylaxis against GvHD. Cyclosporine will be initiated at least 1 day prior to transplant at a dose of 1.5 mg / kg IV q12h (3 mg / kg / day = total daily dose). Dose will thereafter be adjusted to maintain a trough serum level of 200-300 ng /ml. Cyclosporine will be administered intravenously until the patient tolerates full alimentation, at which time conversion to oral dosing to sustain therapeutic levels will be initiated according to standard BMT service guidelines.</description>
    <arm_group_label>TREATMENT OF LYMPHOHEMATOPOIETIC MALIGNANCIES</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Fludarabine, 25mg/m2/d will be administered for each of five days from day -8 to day -4, inclusive. Each dose will be infused intravenously over 30 minutes.</description>
    <arm_group_label>TREATMENT OF LYMPHOHEMATOPOIETIC MALIGNANCIES</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>Melphalan will be administered intravenously over 30 minutes on each of two days from day -3 to day -2, inclusive. The dose for recipients of HLA-matched related grafts will be 50 mg/m2/day x 2. The dose for recipients of HLA-matched unrelated and HLA-single allele disparate related or unrelated marrow or PBSC transplants will be 70 mg/m2/day x 2.</description>
    <arm_group_label>TREATMENT OF LYMPHOHEMATOPOIETIC MALIGNANCIES</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
    <arm_group_label>TREATMENT OF LYMPHOHEMATOPOIETIC MALIGNANCIES</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <arm_group_label>TREATMENT OF LYMPHOHEMATOPOIETIC MALIGNANCIES</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Disease criteria: This trial is primarily designed for: 1) patients with relapsed or
             primary refractory non-Hodgkin's lymphoma, 2) chemosensitive relapsed or refractory
             acute and chronic lymphocytic leukemias, 3) relapsed or primary refractory Hodgkin's
             Disease, or advanced (Durie-Salmon stage II or III) multiple myeloma, advanced
             Waldenstrom macroglobulinemia, who, by virtue of advanced age, intensity of prior
             radiation and/or chemotherapy, history of prior toxicity associated with
             chemo/radiotherapy or existing organ dysfunction, would be at undue risk of regimen
             associated mortality if transplanted according to protocols involving myeloablative
             conditioning regimens.

          -  Patients with aggressive NHL histologies must have chemo/radiosensitive disease, or
             have non-progressive disease, or have stable disease on therapy, and be ineligible for
             an autologous HSC transplant because of disease in the marrow.

          -  Patients with chronic myeloid leukemia and high risk forms of acute myelogenous
             leukemia or myelodysplastic syndromes are also eligible in the absence of an
             alternative active higher priority allogeneic transplant protocol for which they are
             eligible.

          -  Age criteria: Patients may be up to 70 years of age. There is no lower age threshold.
             Patients above the age of 70 may also participate, after evaluation and approval by
             the BMT Service attendings.

          -  Absence of active or uncontrolled bacterial, viral, or fungal infection that would
             contraindicate the use of myelosuppressive chemotherapy.

          -  Patients must have a healthy HLA-compatible donor, either a matched or single HLA
             allele disparate related donor or a similarly compatible unrelated donor recruited
             through the National Marrow Donor Program. Related donors must be willing to
             participate as research subjects and be willing to receive G-CSF to mobilize PBPC and
             undergo leukapheresis to donate PBSC. Unrelated donors identified by the NMDP may
             elect to donate either PBSC after treatment with G-CSF, or bone marrow. These
             unrelated donors will provide informed consent and their PBSC or bone marrow donations
             will be obtained at a qualified donor center participating in the NMDP.

          -  Each patient must be willing to participate as a research subject and must sign an
             informed consent form after discussion of the nature and risks of the study prior to
             entering the protocol. Parents or legal guardians of patients who are minors will sign
             the consent form for these patients after discussion of the nature and risks of the
             study.

        EXCLUSION CRITERIA:

          -  Female patients who are pregnant or lactating.

          -  Active or uncontrolled viral (including HIV-1), bacterial or fungal infection.

          -  Severe renal insufficiency (creatinine &gt;2.0 or creatinine clearance &lt; 30mL/minute)

          -  Severe hepatic dysfunction, as defined by: total bilirubin greater than 2.5 mg/dL and
             AST and ALT &gt;3xnl, unless the liver is involved with disease.

          -  Severe cardiac insufficiency, defined as a resting left ventricular ejection of less
             than 30% as measured by echocardiography or radionuclide cardiac angiography. Patients
             on cardiac medications for congestive heart failure are eligible, as long as their
             LVEF is greater than 30% on medication.

          -  Severe pulmonary insufficiency, as defined by an adjusted diffusing capacity of less
             than 40% of predicted value.

          -  Karnofsky or Lansky score &lt;40%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugo R. Castro-Malaspina, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>November 27, 2012</results_first_submitted>
  <results_first_submitted_qc>December 3, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 7, 2013</results_first_posted>
  <last_update_submitted>December 3, 2012</last_update_submitted>
  <last_update_submitted_qc>December 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>Waldenstr√∂m macroglobulinemia</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>atypical chronic myeloid leukemia, BCR-ABL1 negative</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Protocol Open to Accrual 07/31/2001 Protocol Closed to Accrual 05/23/2006 Primary Completion Date 04/14/2009 Recruitment Location is medical clinic</recruitment_details>
      <pre_assignment_details>Enrolled participants receive preparative cytoreduction prior to transplant.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TREATMENT OF LYMPHOHEMATOPOIETIC MALIGNANCIES</title>
          <description>This is a stratified single-armed phase II study designed to investigate the safety and efficacy of hematopoietic cell allografts administered after nonmyeloablative cytoreduction.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TREATMENT OF LYMPHOHEMATOPOIETIC MALIGNANCIES</title>
          <description>This is a stratified single-armed phase II study designed to investigate the safety and efficacy of hematopoietic cell allografts administered after nonmyeloablative cytoreduction.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.9" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <time_frame>12 months post transplant</time_frame>
        <population>Population is defined as all participants who received transplant as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>TREATMENT OF LYMPHOHEMATOPOIETIC MALIGNANCIES</title>
            <description>This is a stratified single-armed phase II study designed to investigate the safety and efficacy of hematopoietic cell allografts administered after nonmyeloablative cytoreduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <population>Population is defined as all participants who received transplant as per protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <time_frame>24 months post transplant</time_frame>
        <population>Population is defined as all participants who received transplant as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>TREATMENT OF LYMPHOHEMATOPOIETIC MALIGNANCIES</title>
            <description>This is a stratified single-armed phase II study designed to investigate the safety and efficacy of hematopoietic cell allografts administered after nonmyeloablative cytoreduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <population>Population is defined as all participants who received transplant as per protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Acute Graft-versus-Host Disease Matched Related Patients</title>
        <description>Grade III-IV Acute Graft-versus-Host Disease</description>
        <time_frame>up to 4 months post transplant</time_frame>
        <population>The number of matched related patients was analyzed as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Matched Related Patients</title>
          </group>
        </group_list>
        <measure>
          <title>Acute Graft-versus-Host Disease Matched Related Patients</title>
          <description>Grade III-IV Acute Graft-versus-Host Disease</description>
          <population>The number of matched related patients was analyzed as per protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Graft-versus-Host Disease Unrelated and Mismatched Related Patients</title>
        <description>Grade III-IV Acute Graft-versus-Host Disease</description>
        <time_frame>up to 4 months post transplant</time_frame>
        <population>The number of unrelated and mismatched patients was analyzed as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Unrelated and Mismatched Related Patients</title>
          </group>
        </group_list>
        <measure>
          <title>Acute Graft-versus-Host Disease Unrelated and Mismatched Related Patients</title>
          <description>Grade III-IV Acute Graft-versus-Host Disease</description>
          <population>The number of unrelated and mismatched patients was analyzed as per protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extensive Chronic Graft-versus-Host Disease Matched Related Patients</title>
        <time_frame>up to 2 years post transplant</time_frame>
        <population>The number of matched related patients was analyzed as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Matched Related Patients</title>
          </group>
        </group_list>
        <measure>
          <title>Extensive Chronic Graft-versus-Host Disease Matched Related Patients</title>
          <population>The number of matched related patients was analyzed as per protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extensive Chronic Graft-versus-Host Disease Unrelated and Mismatched Related Patients</title>
        <time_frame>up to 2 years post transplant</time_frame>
        <population>The number of unrelated and mismatched patients was analyzed as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Unrelated and Mismatched Related Patients</title>
          </group>
        </group_list>
        <measure>
          <title>Extensive Chronic Graft-versus-Host Disease Unrelated and Mismatched Related Patients</title>
          <population>The number of unrelated and mismatched patients was analyzed as per protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Weekly during the first 3 months post transplant, every 6 weeks during months 3-6 and then 3 month intervals for 1 year post transplant</time_frame>
      <group_list>
        <group group_id="E1">
          <title>TREATMENT OF LYMPHOHEMATOPOIETIC MALIGNANCIES</title>
          <description>This is a stratified single-armed phase II study designed to investigate the safety and efficacy of hematopoietic cell allografts administered after nonmyeloablative cytoreduction.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitut symp, other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with grade 3/4 neut</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Infection w.out neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Transfusion (PLT/BMT)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomatitis/BMT</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>SGOT (AST)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>SGPT (ALT)</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Hugo Castro-Malaspina</name_or_title>
      <organization>Memorial Sloan-Kettering Cancer Center</organization>
      <phone>212-639-8197</phone>
      <email>castro-h@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

